Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer.

ABSTRACT:

Purpose

The JBR.10 trial demonstrated benefit from adjuvant cisplatin/vinorelbine (ACT) in early-stage non-small-cell lung cancer (NSCLC). We hypothesized that expression profiling may identify stage-independent subgroups who might benefit from ACT.

Patients and methods

Gene expression profiling was conducted on mRNA from 133 frozen JBR.10 tumor samples (62 observation [OBS], 71 ACT). The minimum gene set that was selected for the greatest separation of good and poor prognosis patient subgroups in OBS patients was identified. The prognostic value of this gene signature was tested in four independent published microarray data sets and by quantitative reverse-transcriptase polymerase chain reaction (RT-qPCR).

Results

A 15-gene signature separated OBS patients into high-

SUBMITTER: Zhu CQ 

PROVIDER: S-EPMC2988634 | biostudies-literature | 2010 Oct

REPOSITORIES: biostudies-literature